A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

Author(s):
Dissel, J.T. van; Joosten, S.A. (0000-0002-9878-0863); Hoff, S.T.; Soonawala, D.; Prins, C.; Hokey, D.A.; O'Dee, D.M.; Graves, A.; Thierry-Carstensen, B.; Andreasen, L.V.; Ruhwald, M.; Visser, A.W. de; Agger, E.M.; Ottenhoff, T.H.M. (0000-0003-3706-3403); Kromann, I.; Andersen, P.
Published
2014
Publication type
Article / Letter to editor
TuberculosisVaccineClinical trialAdjuvantImmunogenicity
Date issued
2014-12-12
Language
English
Is part of
Vaccine (2014), Vol. 32, no. 52, p. 7098-7107
hdl
1887/104548
doi
10.1016/j.vaccine.2014.10.036